Neuronetics, Inc. is a medical device company that develops and markets non-invasive transcranial magnetic stimulation (TMS) therapies for mental health conditions. Its primary product, the NeuroStar Advanced Therapy System, is FDA-cleared to treat adult patients with major depressive disorder (MDD) who have not responded to prior antidepressant medication, as well as to serve as an adjunct for obsessive-compulsive disorder (OCD) and MDD in adolescents aged 15-21. The company generates revenue through the sale of TMS systems, recurring treatment sessions, and cloud-based practice management solutions. Neuronetics operates Greenbrook, a wholly owned subsidiary that runs treatment centers across the United States. The company serves healthcare providers and patients in the U.S., with marketing authorizations also obtained in the European Union and Japan. Founded in 2003, Neuronetics focuses on expanding its clinical indications and international presence while supporting provider practices with training and reimbursement resources.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage neurostar.com/neuronetics
Sector Healthcare IR page ir.neuronetics.com
Tags
transcranial magnetic stimulation, major depressive disorder, obsessive-compulsive disorder, mental health, non-invasive therapy, treatment centers, practice management software, NeuroStar Advanced Therapy System, Greenbrook, SPRAVATO
Press page —

Metrics

Valuation  
Market cap $ 89.387M
Market cap (USD) $ 89.387M
P/E -3.48
PEG —
P/BV 4.78
P/S 0.56
P/OCF -10.79
P/FCF -9.33
Dividend yield —
Turnover / mcap —
Returns  
ROE -155.7%
ROI -44.2%
ROIC -26.7%
Profit margin -26.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 330.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 149.157M 74.89M 71.348M 65.206M 55.312M 49.244M 62.656M 52.776M 40.433M
Net profit -38.998M -43.708M -30.189M -37.159M -31.193M -27.453M -29.044M -24.097M -16.059M
Free cash flow -21.175M -32.463M -34.407M -34.008M -30.336M -29.12M -31.295M -21.602M -11.738M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 1.38 1.61 2.9 6.87 4.46 11.11 4.49 19.35 —
Price performance 12m -0.14 -0.44 -0.58 0.54 -0.6 1.47 -0.77 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 4.27M 5.62M 6.57M 7.17M 7.71M 13.6M 15.8M 23.4M 16.5M
↳ YoY growth +31.7% +16.9% +9.1% +7.5% +76.4% +16.1% +48.0% -29.5%
↳ 5y CAGR +26.1% +22.9% +28.9% +18.1%
Borrowings, current (USD) — 0.00 — 11.3M — — 13.1M — — —
Borrowings, non-current (USD) — 29.6M 30.4M 19.9M 34.6M 35.3M 22.8M 59.3M 55.2M 65.8M
Lease liabilities (USD) — — — 3.18M 3.72M 4.21M 3.79M 3.19M 27.5M 24.5M
Cash and deposits (USD) 17M 29.1M 105M 75.7M 49M 94.1M 70.3M 59.7M 18.5M 28.1M
Intangible assets (USD) — — — — — — — — 19.6M 18.1M
Right-of-use assets (USD) — — — 3.8M 3.42M 3.88M 3.33M 2.77M 27.1M 23.6M
Net debt (borrowings + leases - cash) (USD) — 409,000 -74.2M -41.4M -10.6M -54.6M -30.6M 2.8M 64.2M 62.2M
Cash flow detail
Operating cash flow (USD) -8.54M -11.1M -20.6M -30.5M -28.4M -28M -30.7M -32M -31M -20.4M
Purchases of property, plant and equipment (USD) -324,000 -594,000 -1.01M -813,000 -730,000 -2.35M -3.27M -2.37M -1.47M -801,000
Change in receivables (cash effect) (USD) -123,000 -690,000 -1.35M -950,000 -597,000 -3.05M -6.32M -8.83M -3.73M 3.54M
Change in inventories (cash effect) (USD) -646,000 -1.07M -435,000 -306,000 -945,000 -3.44M -2.59M -1.1M 3.15M -395,000
Change in payables (cash effect) (USD) 734,000 788,000 606,000 299,000 -1.09M 276,000 -1.97M 2.03M -1.99M -1.75M
Interest paid (cash effect) (USD) -1.41M -2.04M -2.79M -2.95M -3.89M -3.3M -3.54M -4.79M -6.51M -7.59M
Share-based compensation (USD) 161,000 496,000 1.74M 3.43M 4.4M 7.87M 8.75M 7.32M 5.6M 6.85M
Operating cash flow before change in receivables (USD) -8.42M -10.5M -19.2M -29.5M -27.8M -24.9M -24.4M -23.2M -27.3M -23.9M
Free cash flow (OCF - PPE - intangibles) (USD) -8.87M -11.7M -21.6M -31.3M -29.1M -30.3M -34M -34.4M -32.5M -21.2M
Income detail
Research and development expense (USD) 8.22M 7.94M 8.23M 13.7M 9.2M 7.92M 9.34M 9.52M 12.8M 6.58M
↳ 5y CAGR -0.7% +3.3% +2.9% -1.5% -6.5%
Provision for credit losses (USD) 75,000 116,000 153,000 353,000 897,000 -763,000 -341,000 390,000 2.06M 587,000
Credit cost ratio (credit losses / average receivables) (%) — — 3.1% 5.8% 13.1% 10.3% 3.2% 2.7% 10.5% 2.9%
Reported Mar 5, 2019 Mar 5, 2019 Mar 5, 2019 Mar 3, 2020 Mar 2, 2021 Mar 8, 2022 Mar 7, 2023 Mar 8, 2024 Mar 27, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MALVERN, Pa., November 10, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock in the proposed offering will be sold by Neuronetics. In addition, Neuronetics intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

On November 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (“William Blair”), as representative of the underwriters named in Schedule I attached thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 18,750,000 shares (the “Firm Securities”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $1.60 per share (the “Offering”). Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable in whole or in part, at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase an additional 2,812,500 shares of Common Stock (the “Optional Securities,” and together with the Firm Securities, the “Securities”) on the same terms and conditions as the Common Stock sold in the offering. The Company expects the Offering to close on November 12, 2026, subject to the satisfaction of customary closing conditions. All Securities in the Offering are being sold by the Company.

As previously disclosed, on July 25, 2024, Neuronetics, Inc. (the “Company”) entered into a Credit Agreement and Guaranty (as amended, the “Existing Credit Agreement”) with Perceptive Credit Holdings IV, LP (“Perceptive”), as administrative agent and a lender, and the other lenders party thereto. On November 5, 2026, the Company entered into Amendment No. 6 to Credit Agreement and Guaranty by and between the Company, as borrower, and Perceptive, in its capacities as administrative agent for the lender parties thereto and majority lender (the “Perceptive Sixth Amendment”). The Perceptive Sixth Amendment amends the Existing Credit Agreement to, among other things, modify certain revenue covenants, subject to the satisfaction of certain conditions, including, among other things, an optional prepayment in an amount equal to no less than $15,000,000, together with all accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and the lender parties’ other costs and expenses. If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate.

Prompts

Neuronetics, Inc. (ticker STIM), listed in United States.

ETFs Holding Neuronetics, Inc.

ETF Weight in ETF Shares Market value As of
PSIL 3.69% 1,098,644 $ 1.406M Nov 17, 2026